Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238361 | 0.95 | OPRK1 (0.56) | OPRK1HSD11B1ALDH1A1CHIAADORA3 | |
| SCHEMBL6965268 | 0.85 | OPRK1 (0.56) | OPRK1LMNAMAPTKMT2A | |
| SCHEMBL18394828 | 0.85 | USP2 (0.58) | OPRK1HSD11B1ALDH1A1LMNAMAPT | |
| SCHEMBL3532211 | 0.84 | OPRK1 (0.60) | OPRK1HSD11B1ALDH1A1CHIAMAPT | |
| SCHEMBL13116788 | 0.84 | CHIA (0.44) | OPRK1ALDH1A1CHIAMAPK13MAPK12 | |
| SCHEMBL7242387 | 0.84 | MAPT (0.57) | OPRK1HSD11B1ALDH1A1CHIALMNA | |
| SCHEMBL21384397 | 0.84 | OPRK1 (0.56) | OPRK1HSD11B1ALDH1A1CHIALMNA | |
| SCHEMBL12633125 | 0.84 | OPRK1 (0.56) | OPRK1HSD11B1CHIALMNAMAPT | |
| SCHEMBL2222519 | 0.82 | MAPT (0.67) | OPRK1ALDH1A1CHIALMNAMAPT | |
| SCHEMBL15221215 | 0.82 | CHIA (0.42) | OPRK1ALDH1A1CHIAMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010525-B1 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2011-10-27 | — | — | US | disclosed |
| EP-2364303-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | Orion Corporation (FI) | 2011-09-14 | — | — | EP | disclosed |
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807671-B2 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807671-B2 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| WO-2010058060-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2010-05-27 | — | — | WO | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-6133268-A | 1,4-disubstituted piperazines | NOVO NORDISK A/S (DK) | 2000-10-17 | — | — | US | disclosed |
| US-6040302-A | ANTIINFLAMMATORY AGENTS TREATING RHEUMATOID ARTHRITIS, MIGRAINE OR ITCHING, INSULIN RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS AND AGEING-ASSOCIATED OBESITY | NOVO NORDISK A/S (DK) | 2000-03-21 | — | — | US | disclosed |
| US-6004961-A | ANTIINFLAMMATORY AGENTS, ANALGESICS; NON-INSULIN-DEPENDENT DIABETES; AGE-RELATED OBESITY; DIBENZO(D,G)(1,3,6)DIOXAZOCINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-12-21 | — | — | US | disclosed |
| CN-1234799-A | 1,4-disubstituted piperazines | NOVO NORDISK AS (DK) | 1999-11-10 | — | — | CN | disclosed |
| CN-1234797-A | N-substituted azaheterocyclic compound | NOVO NORDISK AS (DK) | 1999-11-10 | — | — | CN | disclosed |
| EP-0934306-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| US-5916889-A | ANTIDIABETIC AGENT; DIETETICS | NOVO NORDISK A/S (DK) | 1999-06-29 | — | — | US | disclosed |
| WO-1998015546-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, DCK, MAVS | OPRK1 186/4885HSD11B1 4825/4885ALDH1A1 1424/4885 |
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ADRA2C, ADRA2A, HTR2C | OPRK1 98/4885HSD11B1 3247/4885ALDH1A1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.